Chongqing Taiji Industry (600129.SH) announced that on December 12, 2024, the company's holding subsidiary Southwest...
According to Zhito Finance APP, Chongqing Taiji Industry (600129.SH) announced that on December 12, 2024, the company's holding subsidiary Southwest Pharmaceutical Co., Ltd. (referred to as: Southwest Pharmaceutical) and Chongqing Taiji Industry SiChuan Taiji Pharmaceutical Co., Ltd. (referred to as: SiChuan Taiji Pharmaceutical) participated in the bidding work organized by the Joint Procurement Office for the 10th batch of national centralized pharmaceutical procurement. Southwest Pharmaceutical's Fluorouracil Injection and SiChuan Taiji Pharmaceutical's Granisetron Hydrochloride Injection are proposed to be selected in this centralized procurement.
Fluorouracil injection passed the national consistency evaluation of quality and efficacy for generic drugs in April 2024. The sales revenue of this pharmaceutical from January to September 2024 is 10.4704 million yuan (unaudited). Granisetron hydrochloride injection passed the national consistency evaluation of quality and efficacy for generic drugs in December 2023. The sales revenue of this pharmaceutical from January to September 2024 is 5.9172 million yuan (unaudited).
This pharmaceutical centralized procurement is the 10th batch of centralized volume-based procurement organized by the state. If Fluorouracil Injection and Granisetron Hydrochloride Injection are confirmed to win the bid, during the procurement period, Medical Institutions will prioritize using the selected pharmaceuticals in this centralized procurement and ensure the completion of the agreed procurement volume. The proposed selected price and proposed selected quantity are based on the final data published by the Joint Procurement Office. If the company subsequently signs the purchase and sale contract and implements it, it will help enhance product competitiveness, increase market share, and strengthen the company's brand influence, having a positive impact on the company's future operating performance.